News | Heart Valve Technology | May 03, 2017

Baylor Jack and Jane Hamilton Heart and Vascular Hospital Implants CoreValve Evolut Pro Valve

Team is first in United States for specific valve-in-valve case

Baylor Jack and Jane Hamilton Heart and Vascular Hospital Implants CoreValve Evolut Pro Valve

May 3, 2017 — The Baylor Jack and Jane Hamilton Heart and Vascular Hospital (BHVH) transcatheter aortic valve replacement (TAVR) team recently placed the first commercially approved CoreValve Evolut Pro system in Texas. This is also the first Evolut Pro valve placed in a failed bioprosthetic (tissue) aortic valve in the United States.

“The Evolut PRO has a unique ‘skirt’ around the valve that helps minimize leakage; one of the greatest potential risks for TAVR patient outcomes,” said Robert Stoler, M.D., co-medical director of cardiology and medical director, Baylor Heart and Vascular Hospital catheterization lab. “In this procedure, we replaced an old, surgically implanted bioprosthetic aortic valve using a minimally invasive approach, without open-heart surgery.”

During a catheter-based TAVR procedure, an interventional cardiologist or cardiothoracic surgeon makes a small incision in the leg (transfemoral approach), upper chest (direct aortic approach) or shoulder (subclavian approach) to access the vasculature, and then guides the new valve into position to replace the failing aortic valve. Once in place, the device expands and takes over the original valves function to enable blood to flow efficiently out of the heart.

“The addition of the Evolut PRO valve to the program at BHVH continues to bring an advanced generation of research and commercially available valves to aortic stenosis patients in the North Texas region,” Stoler added. “We are pleased to be the first in Texas and one of the first in the U.S. to use this new technology.”

Aortic stenosis is a common problem caused by a narrowing of the heart’s aortic valve due to excessive calcium deposits on the valve leaflets. When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body. Eventually, this may cause the heart to weaken, potentially leading to heart failure and increased risk for sudden cardiac death.

Interventional cardiologists and cardiothoracic surgeons on the BHVH medical staff have performed TAVR procedures in patients with aortic stenosis for more than five years and recently reached their 500th TAVR.

For more information:

Related Content

First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Gore Acquires Pipeline Medical Technologies Inc.
News | Heart Valve Technology | September 06, 2018
W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately...
Overlay Init